VONJO™ (pacritinib) Now Approved for the Treatment of Adults with Intermediate or High-Risk Primary or Secondary Myelofibrosis with a Platelet Count Below 50 x 109/L

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360^®, the nation’s leading independent Specialty Pharmacy, has been selected by CTI BioPharma to be a specialty pharmacy partner for VONJO (pacritinib), which is now approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10⁹/L.

“Onco360 is honored to become a specialty pharmacy provider for VONJO patients,” said Benito Fernandez, Chief Commercial Officer, Onco360. “We are committed to supporting the highly specialized needs of myelofibrosis patients with thrombocytopenia and their physicians across the United States.”

According to the Leukemia and Lymphoma Society, myelofibrosis is a rare bone marrow cancer, classified as a myeloproliferative neoplasm (MPNs), which results in the accumulation of fibrous scar tissue within the bone marrow resulting in inadequate hematopoiesis, myelosuppression, fatigue, hepatomegaly, and splenomegaly. Approximately 1.5 myelofibrosis cases per 100,000 people are diagnosed annually in the United States. Most myelofibrosis patients are diagnosed between the ages of 60 and 70 years old. The median survival for patients with myelofibrosis varies dependent upon diagnostic risk stratification but generally ranges from 3.5 to 5.5 years.¹

VONJO is manufactured by CTI BioPharma, a growing biopharmaceutical innovator with global headquarters in Seattle, Washington. The FDA’s approval of VONJO is based upon the results of the PERSIST-2 clinical trial (NCT 02055781). PERSIST-2 was a Phase III trial in which randomized patients with intermediate or high-risk primary or secondary myelofibrosis with splenomegaly and a platelet count <100 x 10⁹/Lto receive VONJO 400 mg orally once, VONJO 200 mg orally twice daily, or best available therapy (BAT). The results of the PERSIST-2 clinical trial indicate that 29% of myelofibrosis patients with baseline platelet levels of less than 50 x 10⁹/L obtained spleen volume reductions of at least 35% during the first six months of VONJO therapy.² Please see the full prescribing information for VONJO at ctibiopharma.com.

About Onco360 Oncology Pharmacy:

Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

References:

1. FS14_Myelofibrosis_Fact Sheet_Final9.12.pdf (lls.org) Accessed on 3/1/2022
2. Accelerated Approval (ctibiopharma.com) Accessed on 3/1/2022